Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

Cancer

Volumn 103, Issue 8, 2005, Pages 1644-1651

  Hornberger, John C ^a,b,c,e   Best, Jennie H ^d  

^a Acumen LLC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NONE   (United States)

Author keywords

Combined cyclophosphamide; Cost benefit; Costs; Doxorubicin; Economics; Lymphoma; Prednisone (CHOP); Rituximab; Vincristine

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER EPIDEMIOLOGY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEATH; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE COURSE; DRUG COST; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG COSTS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MATHEMATICS; MIDDLE AGED; PREDNISONE; QUALITY OF LIFE; SURVIVAL RATE; TIME FACTORS; UNITED STATES; VINCRISTINE;

EID: 16844378957     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20956     Document Type: Article

References (37)

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, Inc., 2002.
2. Yi PI, Coleman M, Saltz L, et al. Chemotherapy for large cell lymphoma: a status update. Semin Oncol. 1990;17:60-73.
3. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma. Ann Oncol. 1997;8:973-978.
4. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224-237.
5. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
7. Boccuti C, Moon M. Comparing Medicare and private insurers: growth rates in spending over three decades. Health Aff (Millwood). 2003;22:230-237.
8. Ubel P, Hirth R, Chernew M, Fendrick A. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
9. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004 (Suppl Web Exclusives): W4-284-W4-296.
10. Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
11. Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant. 2000;6:506-512.
12. Freedman AS, Friedburg JW. Treatment of highly aggressive non-Hodgkin's lymphomas. 2005 UpToDate® online 12.3. Available from URL: http://www.uptodate.com [accessed December 13, 2004].
13. [no authors listed]. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
14. Physican's Desk Reference Staff. 2003 Drug topics (R) red book. Montvale, NJ: Thomson PDR, 2003.
15. Weeks J, Yeap B, Canellos G, Shipp M. Value of follow-up procedures in patients with large cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9:1196-1203.
16. Waters T, Bennett C, Pajeau T, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. 1998;21:641-650.
17. Rizzo J, Vogelsang G, Krumm S, Frink B, Mock V, Bass E. Outpatient-based bone marrow transplantation for haematologic malignancies: Cost saving or cost shifting? J Clin Oncol. 1999;17:2811-2818.
18. Hoover D, Crystal S, Kumar R. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare Current Beneficiary Survey. Health Serv Res. 2002;37:1625-1642.
19. Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood). 2001;20:188-195.
20. Stabler B, Berkowitz LR, Schell MJ, et al. Quality-of-life (QoL) in patients treated with rituximab as a single agent [abstract 2693]. Presented at the 2002 Annual Meeting of the American Society of Clinical Oncology. Available from URL: http://www.asco.org/ac/1,1003,_12-002643-00_18-0016-00_ 19-002639,00asp [accessed December 13, 2004].
21. Doorduijn J, Buijt I, Uyl-de Groot C, van der Holt B, Sonneveld P. Quality of life (QOL) in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP [abstract 1803]. Blood. 2001;98:430a.
22. Mackie M. Hodgkin's disease and non-Hodgkin's lymphoma. In: Black R, Stockton D, editors, for the Scottish Executive Health Department. Cancer scenarios: an aid to planning cancer services in Scotland in the next decade. Edinburgh: The Scottish Executive, 2001. Chapter sections in HTML format available from URL: http://www.show.scot.nhs.uk/sehd/publications/csatp/csatp- 20.htm [accessed December 13, 2004].
23. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health. 2003;6:9-17.
24. Lipscomb J, Weinstein M, Torrence G. Time preference. In: Gold MR, Siegell JE, Russell L, Weinstein M, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996:214-246.
25. Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-3317.
26. Beard SM, Lorigan PC, Sampson FC. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer. 2000;82:81-84.
27. Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996;125:541-548.
28. Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics. 1997;12:89-103.
29. Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur J Cancer. 1996;32A:1510-1517.
30. Uyl-de Groot C, Hagenbeek A, Verdonck L. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant. 1995;16:463-470.
31. Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997;20:445-450.
32. Weeks J, Tierney M, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325:81-86.
33. Armitage J, Cheson B. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol. 1988;6:1335-1347.
34. Coiffier B, Herbrecht R, Tilly H et al. for GELA. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Presented at the 2003 Annual Meeting of the American Society of Clinical Oncology. Abstract and Microsoft® Powerpoint slides available from URL: http://www.asco.org/ac/1,1003,_12-002511- 00_18-0023-00_ 19-001570,00.asp [accessed December 13, 2004].
35. Edelman M, Meyers F, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med. 1997;12:318-331.
36. Report on State of the Art in Blood and Marrow Transplantation: The 2003 BMT summary slides with guide. From the Center for International Blood and Marrow Transplant Research. Newsletter 2004;10(2). PDF and Microsoft® Powerpoint slides available from URL: http://www.ibmtr.org/newsletter/ newsletter_sums.html [accessed December 13, 2004].
37. Weinstein M, Siegel J, Gold M, Kamlet M, Russell L. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.